tetano
Editor, Senior Moderator
Sci Rep. 2016 Jan 21;6:19570. doi: 10.1038/srep19570.
[h=1]Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens.[/h] Knudsen NP[SUP]1[/SUP], Olsen A[SUP]1[/SUP], Buonsanti C[SUP]2[/SUP], Follmann F[SUP]1[/SUP], Zhang Y[SUP]3[/SUP], Coler RN[SUP]4[/SUP], Fox CB[SUP]4[/SUP], Meinke A[SUP]5[/SUP], D Oro U[SUP]2[/SUP], Casini D[SUP]2[/SUP], Bonci A[SUP]2[/SUP], Billeskov R[SUP]1[/SUP], De Gregorio E[SUP]2[/SUP], Rappuoli R[SUP]2[/SUP], Harandi AM[SUP]3[/SUP], Andersen P[SUP]1[/SUP], Agger EM[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The majority of vaccine candidates in clinical development are highly purified proteins and peptides relying on adjuvants to enhance and/or direct immune responses. Despite the acknowledged need for novel adjuvants, there are still very few adjuvants in licensed human vaccines. A vast number of adjuvants have been tested pre-clinically using different experimental conditions, rendering it impossible to directly compare their activity. We performed a head-to-head comparison of five different adjuvants Alum, MF59?, GLA-SE, IC31? and CAF01 in mice and combined these with antigens from M. tuberculosis, influenza, and chlamydia to test immune-profiles and efficacy in infection models using standardized protocols. Regardless of antigen, each adjuvant had a unique immunological signature suggesting that the adjuvants have potential for different disease targets. Alum increased antibody titers; MF59? induced strong antibody and IL-5 responses; GLA-SE induced antibodies and Th1; CAF01 showed a mixed Th1/Th17 profile and IC31? induced strong Th1 responses. MF59? and GLA-SE were strong inducers of influenza HI titers while CAF01, GLA-SE and IC31? enhanced protection to TB and chlamydia. Importantly, this is the first extensive attempt to categorize clinical-grade adjuvants based on their immune profiles and protective efficacy to inform a rational development of next generation vaccines for human use.
PMID: 26791076 [PubMed - in process] Free full text
[h=1]Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens.[/h] Knudsen NP[SUP]1[/SUP], Olsen A[SUP]1[/SUP], Buonsanti C[SUP]2[/SUP], Follmann F[SUP]1[/SUP], Zhang Y[SUP]3[/SUP], Coler RN[SUP]4[/SUP], Fox CB[SUP]4[/SUP], Meinke A[SUP]5[/SUP], D Oro U[SUP]2[/SUP], Casini D[SUP]2[/SUP], Bonci A[SUP]2[/SUP], Billeskov R[SUP]1[/SUP], De Gregorio E[SUP]2[/SUP], Rappuoli R[SUP]2[/SUP], Harandi AM[SUP]3[/SUP], Andersen P[SUP]1[/SUP], Agger EM[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The majority of vaccine candidates in clinical development are highly purified proteins and peptides relying on adjuvants to enhance and/or direct immune responses. Despite the acknowledged need for novel adjuvants, there are still very few adjuvants in licensed human vaccines. A vast number of adjuvants have been tested pre-clinically using different experimental conditions, rendering it impossible to directly compare their activity. We performed a head-to-head comparison of five different adjuvants Alum, MF59?, GLA-SE, IC31? and CAF01 in mice and combined these with antigens from M. tuberculosis, influenza, and chlamydia to test immune-profiles and efficacy in infection models using standardized protocols. Regardless of antigen, each adjuvant had a unique immunological signature suggesting that the adjuvants have potential for different disease targets. Alum increased antibody titers; MF59? induced strong antibody and IL-5 responses; GLA-SE induced antibodies and Th1; CAF01 showed a mixed Th1/Th17 profile and IC31? induced strong Th1 responses. MF59? and GLA-SE were strong inducers of influenza HI titers while CAF01, GLA-SE and IC31? enhanced protection to TB and chlamydia. Importantly, this is the first extensive attempt to categorize clinical-grade adjuvants based on their immune profiles and protective efficacy to inform a rational development of next generation vaccines for human use.
PMID: 26791076 [PubMed - in process] Free full text